CA2578078A1 - Sensor - Google Patents
Sensor Download PDFInfo
- Publication number
- CA2578078A1 CA2578078A1 CA002578078A CA2578078A CA2578078A1 CA 2578078 A1 CA2578078 A1 CA 2578078A1 CA 002578078 A CA002578078 A CA 002578078A CA 2578078 A CA2578078 A CA 2578078A CA 2578078 A1 CA2578078 A1 CA 2578078A1
- Authority
- CA
- Canada
- Prior art keywords
- sensor
- patient
- pco2
- skin
- sensing device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 34
- 238000005259 measurement Methods 0.000 claims abstract description 23
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 12
- 239000001301 oxygen Substances 0.000 claims abstract description 12
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 9
- 230000036961 partial effect Effects 0.000 claims abstract description 8
- 230000036760 body temperature Effects 0.000 claims abstract description 5
- 239000012528 membrane Substances 0.000 claims description 46
- 239000007788 liquid Substances 0.000 claims description 40
- 238000003780 insertion Methods 0.000 claims description 37
- 230000037431 insertion Effects 0.000 claims description 37
- 239000000853 adhesive Substances 0.000 claims description 22
- 230000001070 adhesive effect Effects 0.000 claims description 16
- 210000001519 tissue Anatomy 0.000 description 24
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 206010040047 Sepsis Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000004033 plastic Substances 0.000 description 9
- 229920003023 plastic Polymers 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000006213 oxygenation reaction Methods 0.000 description 6
- 239000011505 plaster Substances 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- 229920000271 Kevlar® Polymers 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 239000000645 desinfectant Substances 0.000 description 3
- -1 hydroxyl ions Chemical class 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000004761 kevlar Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 229920002379 silicone rubber Polymers 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020591 Hypercapnia Diseases 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000004945 silicone rubber Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000005391 art glass Substances 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 239000012858 resilient material Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005428 wave function Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
- A61B5/14552—Details of sensors specially adapted therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1473—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/412—Detecting or monitoring sepsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/683—Means for maintaining contact with the body
- A61B5/6832—Means for maintaining contact with the body using adhesives
- A61B5/6833—Adhesive patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
- A61B5/6848—Needles
- A61B5/6849—Needles in combination with a needle set
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
A physiological sensing device comprises, in combination a sensor (4) for the measurement of the partial pressure of carbon dioxide (pCO2), a body temperature sensor (5) and a heart rate and oxygen saturation sensor (54). The sensor device can be used to continuously monitor the vital signs of a patient.
Description
Sensor The invention relates to a physiological sensor.
A simple sensor particularly suitable for partial pressure of carbon dioxide (pCO2) measurement, especially as part of a technique for monitoring for ischemias, is described in WO 00/04386.
In addition to the detection of ischemia, it has now been realised that the measurement of pCO2 may be useful in the diagnosis of severe and potentially life threatening conditions leading to changes in e.g. blood perfusion of tissues, respiration and/or the metabolism, such as shock and sepsis. Thus, it would be advantageous to provide a sensing device which is particularly suited to the monitoring of the hospitalised patient, also outside intensive care units, to detect the onset of sepsis.
Viewed from a first aspect, the present invention provides a physiological sensing device comprising in combination:
a sensor for the measurement of the partial pressure of carbon dioxide (PCO2);
a body temperature sensor;
a heart rate sensor; and an oxygen saturation sensor.
Thus, according to the invention a single device can be provided which measures key vital signs such as pCO2a body temperature, pulse and blood oxygenation. It is believed that the measurement and monitoring of just these four parameters allows a physician to identify the onset of critical and treatment-requiring conditions in a patient such as, for example, sepsis. Consequently, the device according to the invention allows a physician to conveniently and accurately monitor a patient for the onset of sepsis.
In general, the pCO2 sensor is configured for insertion through a patient's skin. In this way, the sensor may be inserted into the tissue, for example a muscle, of the patient. Thus, the sensor may be dimensioned for insertion into the tissue of a patient with minimal disruption to the tissue. The pCOa sensor may be configured to penetrate the patient's skin (and tissue). Consequently, the pCO2 sensor or the device in general, may be provided with a sharp, for example pointed, tip.
Alternatively, the pCO2 sensor may be configured for insertion into an incision in the patient's tissue.
Viewed from a fiuther aspect, therefore, the invention also provides a physiological sensing device comprising a pCO2 sensor configured for insertion through a patient's skin and a sharp tip for puncturing a patient's skin on insertion of the pCO2 sensor.
The sensor device may be provided with an insertion device for inserting the pCO2 sensor through the patient's skin. In one embodiment, the insertion device is a removable mandrel which is received in a sheath connected to the pCO2 sensor and engages the pCO2 sensor to force it through the patient's skin. The mandrel may be removed once the pCO2 sensor has been inserted in the patient's tissue.
Alternatively, the sensor device may comprise a hollow needle in which the pCO2 sensor is received for insertion through a patient's skin. The hollow needle may be removable from the sensor device after insertion of the pCO2 sensor.
Advantageously, the cross-section of the needle may be an open curve. This has the advantage that the electrical connections to the pCO2 sensor can pass through the needle and can be separated from the needle when the needle is removed from the patient. For example, the needle may has a cross-section that is U-shaped, V-shaped or C-shaped.
Advantageously, the device is provided with a self-sealing membrane to close the hole for the needle (or other insertion device) when the needle is removed.
Advantageously, the sensor device and/or the insertion device may be provided with disinfectant, particularly on the pCOa sensor, temperature sensor or sharp tip, in order that the sensor device can be applied quickly to a patient, for example in an emergency. Thus, the sensor device may be packaged with disinfectant on those surfaces that will contact the patient.
The pCO2 sensor may be connected to an electrical cable for communicating signals from the sensor and connected electrically at its distal end to the sensor. The device may comprise a sheath mechanically connected to the pCO2 sensor and extending with and surrounding at least a portion of the length of the cable.
In one arrangement, the sheath comprises a plurality of substantially longitudinally extending flexible portions separated by a plurality of longitudinal slits, such that movement of the proximal end of the sheath towards the distal end of the sheath shortens the distance.between the ends of the flexible portions and causes the flexible portions to project outwardly and thereby increase the effective diameter of the sheath in the region of the flexible portions, such that the pCO2 sensor can be retained in tissue by the projecting flexible portions.
Thus, according to this arrangement, the sensor can be inserted into the patient's tissue and the cable can be pulled to draw the ends of the flexible portions together and cause them to project outwardly. The projecting flexible portions engage with the patient's tissue and retain the pCO2 sensor in position while the sensor monitors the physiology of the organ. When monitoring is complete, the proximal end of the sheath can be released so that the flexible portions return to their original position flush with the sheath and disengage the tissue. The sensor can then be removed easily from the patient.
The flexible portions may be resilient, for example composed of a resilient material. The flexible portions may be biased into the flush position, for example by their own resilience or by a separate resilient component.
A locking mechanism may be provided, for example at the proximal end of the sheath, to maintain the ends of the sheath in the position in which the flexible members project outwardly.
The device may further comprise a line, for example a Kevlar line, which is mechanically connected to the distal end of the sheath. The line may extend longitudinally with the cable to assist in pulling the distal end of the sheath towards the proximal end of the sheath. Such a line has the advantage that it is not necessary for the cable and/or the electrical connections to the sensor to be strong enough to withstand the forces necessary to bow the flexible members.
It is possible that the cable may be surrounded by a further conduit in addition to the sheath, but this is not preferred. In a simple embodiment, the cable is surrounded only by the sheath.
A simple sensor particularly suitable for partial pressure of carbon dioxide (pCO2) measurement, especially as part of a technique for monitoring for ischemias, is described in WO 00/04386.
In addition to the detection of ischemia, it has now been realised that the measurement of pCO2 may be useful in the diagnosis of severe and potentially life threatening conditions leading to changes in e.g. blood perfusion of tissues, respiration and/or the metabolism, such as shock and sepsis. Thus, it would be advantageous to provide a sensing device which is particularly suited to the monitoring of the hospitalised patient, also outside intensive care units, to detect the onset of sepsis.
Viewed from a first aspect, the present invention provides a physiological sensing device comprising in combination:
a sensor for the measurement of the partial pressure of carbon dioxide (PCO2);
a body temperature sensor;
a heart rate sensor; and an oxygen saturation sensor.
Thus, according to the invention a single device can be provided which measures key vital signs such as pCO2a body temperature, pulse and blood oxygenation. It is believed that the measurement and monitoring of just these four parameters allows a physician to identify the onset of critical and treatment-requiring conditions in a patient such as, for example, sepsis. Consequently, the device according to the invention allows a physician to conveniently and accurately monitor a patient for the onset of sepsis.
In general, the pCO2 sensor is configured for insertion through a patient's skin. In this way, the sensor may be inserted into the tissue, for example a muscle, of the patient. Thus, the sensor may be dimensioned for insertion into the tissue of a patient with minimal disruption to the tissue. The pCOa sensor may be configured to penetrate the patient's skin (and tissue). Consequently, the pCO2 sensor or the device in general, may be provided with a sharp, for example pointed, tip.
Alternatively, the pCO2 sensor may be configured for insertion into an incision in the patient's tissue.
Viewed from a fiuther aspect, therefore, the invention also provides a physiological sensing device comprising a pCO2 sensor configured for insertion through a patient's skin and a sharp tip for puncturing a patient's skin on insertion of the pCO2 sensor.
The sensor device may be provided with an insertion device for inserting the pCO2 sensor through the patient's skin. In one embodiment, the insertion device is a removable mandrel which is received in a sheath connected to the pCO2 sensor and engages the pCO2 sensor to force it through the patient's skin. The mandrel may be removed once the pCO2 sensor has been inserted in the patient's tissue.
Alternatively, the sensor device may comprise a hollow needle in which the pCO2 sensor is received for insertion through a patient's skin. The hollow needle may be removable from the sensor device after insertion of the pCO2 sensor.
Advantageously, the cross-section of the needle may be an open curve. This has the advantage that the electrical connections to the pCO2 sensor can pass through the needle and can be separated from the needle when the needle is removed from the patient. For example, the needle may has a cross-section that is U-shaped, V-shaped or C-shaped.
Advantageously, the device is provided with a self-sealing membrane to close the hole for the needle (or other insertion device) when the needle is removed.
Advantageously, the sensor device and/or the insertion device may be provided with disinfectant, particularly on the pCOa sensor, temperature sensor or sharp tip, in order that the sensor device can be applied quickly to a patient, for example in an emergency. Thus, the sensor device may be packaged with disinfectant on those surfaces that will contact the patient.
The pCO2 sensor may be connected to an electrical cable for communicating signals from the sensor and connected electrically at its distal end to the sensor. The device may comprise a sheath mechanically connected to the pCO2 sensor and extending with and surrounding at least a portion of the length of the cable.
In one arrangement, the sheath comprises a plurality of substantially longitudinally extending flexible portions separated by a plurality of longitudinal slits, such that movement of the proximal end of the sheath towards the distal end of the sheath shortens the distance.between the ends of the flexible portions and causes the flexible portions to project outwardly and thereby increase the effective diameter of the sheath in the region of the flexible portions, such that the pCO2 sensor can be retained in tissue by the projecting flexible portions.
Thus, according to this arrangement, the sensor can be inserted into the patient's tissue and the cable can be pulled to draw the ends of the flexible portions together and cause them to project outwardly. The projecting flexible portions engage with the patient's tissue and retain the pCO2 sensor in position while the sensor monitors the physiology of the organ. When monitoring is complete, the proximal end of the sheath can be released so that the flexible portions return to their original position flush with the sheath and disengage the tissue. The sensor can then be removed easily from the patient.
The flexible portions may be resilient, for example composed of a resilient material. The flexible portions may be biased into the flush position, for example by their own resilience or by a separate resilient component.
A locking mechanism may be provided, for example at the proximal end of the sheath, to maintain the ends of the sheath in the position in which the flexible members project outwardly.
The device may further comprise a line, for example a Kevlar line, which is mechanically connected to the distal end of the sheath. The line may extend longitudinally with the cable to assist in pulling the distal end of the sheath towards the proximal end of the sheath. Such a line has the advantage that it is not necessary for the cable and/or the electrical connections to the sensor to be strong enough to withstand the forces necessary to bow the flexible members.
It is possible that the cable may be surrounded by a further conduit in addition to the sheath, but this is not preferred. In a simple embodiment, the cable is surrounded only by the sheath.
Advantageously, the sheath may form a carbon dioxide permeable membrane of the pCOz sensor. This provides a particularly simple construction. Suitable materials for the sheath in this case are PTFE, silicone rubbers and polyolefins.
The sensor device may be provided with an attachment portion for attaching the device to the surface of the patient's skin. In one convenient embodiment, the attachment portion is an adhesive patch, such as a plaster. In the context of a pCO2 sensor, this is believed to be a novel aspect of the invention. Thus, viewed from a further aspect, the invention provides a physiological sensing device comprising a pCOa sensor configured for insertion through a patient's skin and an adhesive patch for adhering the device to a patient's skin to retain the inserted pCO2 sensor in position.
The provision of a plaster, as well as retaining the sensor device in position, has several other advantages. In particular, the plaster seals the point at which the pCOz sensor is inserted through the patient's skin, thereby reducing the risk of infection. In this regard, the patient-facing side of the plaster may be provided with disinfectant or antibiotics. Furthermore, the plaster may conveniently carry wires, other sensors or a wireless communication device.
Such a device is conveniently applied to the patient and retained in position while the patient is monitored. Desirably, the electrical and mechanical connections to the pCO2 sensor, such as electrical cables and sheaths are flexible. In this way, the discomfort to the patient when the pCOa sensor has been inserted is minimised.
The sensor may comprise a closed chamber bounded, at least partially, by a carbon dioxide permeable membrane; and at least two electrodes within the chamber, with the chamber containing substantially electrolyte-free liquid in contact with the electrodes and the membrane.
By substantially electrolyte-free, it is meant that the liquid has an ionic osmolality no greater than that at 37 C of an aqueous 5 mM sodium chloride solution, preferably no more than that of a 500 M sodium chloride solution, more especially no more than that of a 10'5 to 10"6 M HCl solution.
Preferably, the liquid in contact with the electrodes is aqueous and especially preferably it is water, substantially electrolyte-free as defined above. Other solvents that react with CO2 to increase or decrease their conductance, e.g. by the production or neutralization of ions, may likewise be used. In practice, however, deionized or distilled water with or without the addition of a strong acid (e.g. HCl) to a concentration of 0.1 to 100 M, preferably 0.5 to 50 M, more especially about M, has been found to function particularly well. The function of this small addition of acid is generally to maintain the pH of the liquid at 6 or below to avoid significant contributions to conductance by hydroxyl ions and to maintain the linearity of the measurements of pCO2.
The liquid may contain a non-ionic excipient. In this way, the osmolarity of the liquid in the chamber can be increased to prevent egress of the liquid across the membrane, without affecting the electrical characteristics of the liquid.
The excipient should have at least isotonic concentration, i.e. should be isosinotic with an aqueous solution of 0.9% w/v NaCI. Preferably, the concentration of the excipient is hypertonic, i.e. is hyperosmotic with 0.9% w/v aqueous NaCI.
Thus, the osmolality of the excipient in the chamber may be greater than that of 0.9% w/v aqueous NaCl, preferably greater than that of 1.8% w/v aqueous NaCl (twice isotonic concentration). Osmolalities greater than that of 4.5% w/v aqueous NaCI (five times isotonic concentration), or even greater than that of 9% w/v aqueous NaCl (ten times isotonic concentration) may be used.
Any suitable excipient may be used that is inert to the bicarbonate reaction in the chamber. The excipient should also be soluble in the liquid, for example water.
The excipient is also desirably an accepted pharmaceutical excipient for intravenous use and with low viscosity for simple filling of the chamber. The excipient should preferably be sterilizable and storage stable. Desirably, the excipient should inhibit microbiological growth.
A suitable excipient is polyethylene glycol (PEG)and the presently preferred excipient is propylene glycol.
The primary components of the pCO2 sensor are an electrode chamber, a COZ-permeable membrane forming at least part of the wall of the electrode chamber, first and second electrodes having surfaces within said chamber (or providing internal surfaces to said chamber), and a liquid (generally substantially electrolyte-free water) in the electrode chamber in contact with the membrane and the first and second electrodes. The sensor includes or is connectable to an AC power supply, a conductance (or resistance) determining device, a signal generator (which may be part of the determining means) and optionally a signal transmitter.
The mechanism by which pCO2 is determined using the sensor device of the invention is straightforward. In a pure protic solvent, e.g. water, the electrical resistance is high because of the paucity of ionic species. Addition of CO2 results in formation (with water) of H+ and HCO"3 ions and thus a reduction in the electrical resistance. Since the only factor responsible for reduction in resistance in the sensor is CO2 passing through the membrane, the change in resistance enables pCO2 to be measured.
From the equilibrium constant for the HaO + CO2 to H+ + HCO-3 equilibrium, COa concentration is equal to apCO2 (where a at 25 C is 0.310).
The electrical conductivity for protons is GH+ = 349.8 S.cm2/mol, that for hydroxyls is GoH- = 198.3 S.cm2/mol and that for bicarbonate is GHCO3- = 44.5 S.cm2/mol.
The concentrations of H+ and OI-F vary inversely, and the concentrations of H+ and HCO3 are directly proportional to pCO2. The total conductance of the solution is thus effectively proportional to pCOa since the contribution of OI-r is minimal. The conductivity of the solution G,,,1õuon is thus given by GsoluGon = 8H+[W]GH+ + eOH-[OH ]CTOH- + OHCO-3 [HC03 ]GHC03-where OH-, OOH- and 8HC03- are the activity coefficients for the three ionic species.
Table I below shows, by way of example, measured pCO2 and pH values and coiTesponding calculated values for H+, OH- and HC03 concentrations showing the increase of H+ and HC03- with increasing pCO2.
Sample number pC02 (kPa) pH [ffT- [OH) [HCO31 (mmo1/1) (mmol/1) (mmol/1) 1 6.38 5.141 7.23E-06 1.38E-09 7.23E-06 2 9.64 5.060 8.71E-06 1.15E-09 8.71E-06 3 15.37 4.891 1.29E-05 7.78E-10 1.29E-05 4 25.88 4.760 1.74E-05 5.75E-10 1.74E-05 5 31.48 4.664 2.17E-05 4.61E-10 2.17E-05 (pCO2 and pH measured with a standard blood gas analyser, ABL System 625 at 37 C) The electrical conductivity is measured in the solvent rilm in the pCO2 sensor of the invention. This can be done by applying a constant voltage (or current) to the electrodes and measuring the current (or voltage) changes which correspond to changes in conductivity as CO2 enters the solvent through the membrane.
Preferably however an alternating sine wave function voltage with a constant peak value is applied and the voltage drop across the electrodes is measured. The solution conductivity is then equal to the current passed through the electrode divided by the voltage drop across the electrodes.
The pCOa sensor may function by applying an alternating electrical potential to the electrodes whereby to cause an alternating current in the liquid. The liquid should be reactive with carbon dioxide to alter its conductance. The electrical potential may have a frequency of 20 to 10,000 Hz, preferably 100 to 4,000 Hz.
The pCO2 sensors of the invention are provided with or are connectable to an electrical power source arranged to apply an alternating electrical potential across the electrodes with a frequency of 100 to 10,000 Hz. The frequency is preferably greater than 1 kHz. The frequency is preferably less than 5 kHz, more preferably less than 2 kHz. At frequencies below 100 Hz, the sensitivity of pCO2 determination is lower due to electropolarization and moreover the instrument response time becomes overly slow, while at frequencies above 10 kHz sensitivity is again less due to the low impedance of the capacitances in the sensor.
The power source may be an AC power source or alternatively a DC source in conjunction with an oscillator, i.e. a combination which together constitutes an AC power source.
The power supply is preferably such that the maximum current density through the liquid at the electrodes is no more than 50 A/m2, preferably no more than 30 A/m2, more preferably no more than 20 A/m2, in particular no more than A/m2, and most preferably about 1 A/m2 or below. Higher current density values of 20 A/rn2 or greater should only be used at the higher frequencies, e.g. 1-10 kHz.
The smallest maximum current density is determined by detection limits, but values down to 10-8 A/m2 are usable. The smallest maximum current density however will generally be at least 0.1 A/ma.
By operating at such current densities and voltage frequencies, and by appropriate construction, the sensor can determine the conductance/resistance of the liquid into which the CO2 migrates without any significant loss of accuracy arising as a result of the electropolarization of the electrodes.
For particularly high accuracy, the potential or current across the electrodes (and hence the resistance or conductance of the liquid between the electrodes) is determined using a lock-in amplifier set to the same frequency as that of the voltage generator or electrical power source.
Furthermore it is preferred to incorporate in the detection a high pass filter to screen out current with a frequency less than 100 Hz, preferably less than 150 Hz.
The filter is preferably a passive filter, for example a capacitor and a resistor.
The power source and the detector circuitry may, if desired, be included in the sensor of the invention. In this case, if it is desired that the sensor be wireless, it will preferably also be provided with means enabling the signal to be detected remotely, e.g. a transmitter, for example a RF transmitter.
A further electrode may be provided that is electrically connected to the patient, for example to the patient's skin. The signal from this fu.rther electrode may be processed with the signal from the sensor in order to compensate for electromagnetic noise from the patient.
Electropolarization effects are considerably reduced by increasing the surface area of the electrodes in contact with the liquid, e.g. by siting the electrodes in wells disposed away from the plane of the membrane or by using non-planar electrode surfaces, e.g. rough or textured surfaces. In general therefore it is desirable to have as large a ratio of surface area of electrode to liquid contact as possible, and as shallow as possible a liquid depth over as much as possible of its area of contact with the membrane. In this way the response time is reduced, electropolarization is reduced, lower frequencies may be used and stray capacitance effects are considerably reduced.
Increased electrical resistance relative to the resistance at the electrodes may be achieved by restricting the cross sectional area of the electrical path through the liquid between the electrodes at a zone in which the liquid is in contact with the membrane, e.g. by decreasing the depth of the liquid for a part of the path between the electrodes, and/or by ensuring a relatively large area of contact between each electrode and the liquid.
The resistance of the liquid at the membrane and between the electrodes may be increased by the use of structural elements to define liquid channels across the membrane between the electrodes, e.g. by disposing the membrane across or adjacent an insulating chamber wall portion in which such channels are formed, for example by etching. Likewise a porous spacer may be disposed between the membrane and the chamber wall to define the depth of the liquid.
Indeed, such spacers are important to use where, under the pressure conditions experienced in use, the membrane is sufficiently flexible and the liquid depth behind the membrane sufficiently small, for the measured conductance to vary with pressure.
In a preferred arrangement, the pCO2 sensor comprises:
a sensor body having a longitudinal axis;
at least two electrodes spaced in a direction transverse to the longitudinal axis of the sensor body;
a plurality of support members extending outwardly from the axis of the sensor body and defining between adjacent support members at least one liquid channel that provides a fluid pathway between the electrodes; and a gas-permeable membrane supported by the support members and providing an outer wall of the liquid channel(s).
This arrangement provides a compact configuration of the sensor with a longitudinal geometry that is suited to insertion in the tissue of a patient.
Furthermore, the support members are able to provide physical support to the membrane, as well as defining liquid channels of small cross-sectional area that allow accurate measurement.
In order to reduce the electropolarisation effect mentioned above, the electrodes may be located in a recess in the sensor body that has a greater cross-sectional area than the liquid channels. In this way, the current density around the electrodes is reduced by the greater volume for liquid.
The sensor device may be provided with an attachment portion for attaching the device to the surface of the patient's skin. In one convenient embodiment, the attachment portion is an adhesive patch, such as a plaster. In the context of a pCO2 sensor, this is believed to be a novel aspect of the invention. Thus, viewed from a further aspect, the invention provides a physiological sensing device comprising a pCOa sensor configured for insertion through a patient's skin and an adhesive patch for adhering the device to a patient's skin to retain the inserted pCO2 sensor in position.
The provision of a plaster, as well as retaining the sensor device in position, has several other advantages. In particular, the plaster seals the point at which the pCOz sensor is inserted through the patient's skin, thereby reducing the risk of infection. In this regard, the patient-facing side of the plaster may be provided with disinfectant or antibiotics. Furthermore, the plaster may conveniently carry wires, other sensors or a wireless communication device.
Such a device is conveniently applied to the patient and retained in position while the patient is monitored. Desirably, the electrical and mechanical connections to the pCO2 sensor, such as electrical cables and sheaths are flexible. In this way, the discomfort to the patient when the pCOa sensor has been inserted is minimised.
The sensor may comprise a closed chamber bounded, at least partially, by a carbon dioxide permeable membrane; and at least two electrodes within the chamber, with the chamber containing substantially electrolyte-free liquid in contact with the electrodes and the membrane.
By substantially electrolyte-free, it is meant that the liquid has an ionic osmolality no greater than that at 37 C of an aqueous 5 mM sodium chloride solution, preferably no more than that of a 500 M sodium chloride solution, more especially no more than that of a 10'5 to 10"6 M HCl solution.
Preferably, the liquid in contact with the electrodes is aqueous and especially preferably it is water, substantially electrolyte-free as defined above. Other solvents that react with CO2 to increase or decrease their conductance, e.g. by the production or neutralization of ions, may likewise be used. In practice, however, deionized or distilled water with or without the addition of a strong acid (e.g. HCl) to a concentration of 0.1 to 100 M, preferably 0.5 to 50 M, more especially about M, has been found to function particularly well. The function of this small addition of acid is generally to maintain the pH of the liquid at 6 or below to avoid significant contributions to conductance by hydroxyl ions and to maintain the linearity of the measurements of pCO2.
The liquid may contain a non-ionic excipient. In this way, the osmolarity of the liquid in the chamber can be increased to prevent egress of the liquid across the membrane, without affecting the electrical characteristics of the liquid.
The excipient should have at least isotonic concentration, i.e. should be isosinotic with an aqueous solution of 0.9% w/v NaCI. Preferably, the concentration of the excipient is hypertonic, i.e. is hyperosmotic with 0.9% w/v aqueous NaCI.
Thus, the osmolality of the excipient in the chamber may be greater than that of 0.9% w/v aqueous NaCl, preferably greater than that of 1.8% w/v aqueous NaCl (twice isotonic concentration). Osmolalities greater than that of 4.5% w/v aqueous NaCI (five times isotonic concentration), or even greater than that of 9% w/v aqueous NaCl (ten times isotonic concentration) may be used.
Any suitable excipient may be used that is inert to the bicarbonate reaction in the chamber. The excipient should also be soluble in the liquid, for example water.
The excipient is also desirably an accepted pharmaceutical excipient for intravenous use and with low viscosity for simple filling of the chamber. The excipient should preferably be sterilizable and storage stable. Desirably, the excipient should inhibit microbiological growth.
A suitable excipient is polyethylene glycol (PEG)and the presently preferred excipient is propylene glycol.
The primary components of the pCO2 sensor are an electrode chamber, a COZ-permeable membrane forming at least part of the wall of the electrode chamber, first and second electrodes having surfaces within said chamber (or providing internal surfaces to said chamber), and a liquid (generally substantially electrolyte-free water) in the electrode chamber in contact with the membrane and the first and second electrodes. The sensor includes or is connectable to an AC power supply, a conductance (or resistance) determining device, a signal generator (which may be part of the determining means) and optionally a signal transmitter.
The mechanism by which pCO2 is determined using the sensor device of the invention is straightforward. In a pure protic solvent, e.g. water, the electrical resistance is high because of the paucity of ionic species. Addition of CO2 results in formation (with water) of H+ and HCO"3 ions and thus a reduction in the electrical resistance. Since the only factor responsible for reduction in resistance in the sensor is CO2 passing through the membrane, the change in resistance enables pCO2 to be measured.
From the equilibrium constant for the HaO + CO2 to H+ + HCO-3 equilibrium, COa concentration is equal to apCO2 (where a at 25 C is 0.310).
The electrical conductivity for protons is GH+ = 349.8 S.cm2/mol, that for hydroxyls is GoH- = 198.3 S.cm2/mol and that for bicarbonate is GHCO3- = 44.5 S.cm2/mol.
The concentrations of H+ and OI-F vary inversely, and the concentrations of H+ and HCO3 are directly proportional to pCO2. The total conductance of the solution is thus effectively proportional to pCOa since the contribution of OI-r is minimal. The conductivity of the solution G,,,1õuon is thus given by GsoluGon = 8H+[W]GH+ + eOH-[OH ]CTOH- + OHCO-3 [HC03 ]GHC03-where OH-, OOH- and 8HC03- are the activity coefficients for the three ionic species.
Table I below shows, by way of example, measured pCO2 and pH values and coiTesponding calculated values for H+, OH- and HC03 concentrations showing the increase of H+ and HC03- with increasing pCO2.
Sample number pC02 (kPa) pH [ffT- [OH) [HCO31 (mmo1/1) (mmol/1) (mmol/1) 1 6.38 5.141 7.23E-06 1.38E-09 7.23E-06 2 9.64 5.060 8.71E-06 1.15E-09 8.71E-06 3 15.37 4.891 1.29E-05 7.78E-10 1.29E-05 4 25.88 4.760 1.74E-05 5.75E-10 1.74E-05 5 31.48 4.664 2.17E-05 4.61E-10 2.17E-05 (pCO2 and pH measured with a standard blood gas analyser, ABL System 625 at 37 C) The electrical conductivity is measured in the solvent rilm in the pCO2 sensor of the invention. This can be done by applying a constant voltage (or current) to the electrodes and measuring the current (or voltage) changes which correspond to changes in conductivity as CO2 enters the solvent through the membrane.
Preferably however an alternating sine wave function voltage with a constant peak value is applied and the voltage drop across the electrodes is measured. The solution conductivity is then equal to the current passed through the electrode divided by the voltage drop across the electrodes.
The pCOa sensor may function by applying an alternating electrical potential to the electrodes whereby to cause an alternating current in the liquid. The liquid should be reactive with carbon dioxide to alter its conductance. The electrical potential may have a frequency of 20 to 10,000 Hz, preferably 100 to 4,000 Hz.
The pCO2 sensors of the invention are provided with or are connectable to an electrical power source arranged to apply an alternating electrical potential across the electrodes with a frequency of 100 to 10,000 Hz. The frequency is preferably greater than 1 kHz. The frequency is preferably less than 5 kHz, more preferably less than 2 kHz. At frequencies below 100 Hz, the sensitivity of pCO2 determination is lower due to electropolarization and moreover the instrument response time becomes overly slow, while at frequencies above 10 kHz sensitivity is again less due to the low impedance of the capacitances in the sensor.
The power source may be an AC power source or alternatively a DC source in conjunction with an oscillator, i.e. a combination which together constitutes an AC power source.
The power supply is preferably such that the maximum current density through the liquid at the electrodes is no more than 50 A/m2, preferably no more than 30 A/m2, more preferably no more than 20 A/m2, in particular no more than A/m2, and most preferably about 1 A/m2 or below. Higher current density values of 20 A/rn2 or greater should only be used at the higher frequencies, e.g. 1-10 kHz.
The smallest maximum current density is determined by detection limits, but values down to 10-8 A/m2 are usable. The smallest maximum current density however will generally be at least 0.1 A/ma.
By operating at such current densities and voltage frequencies, and by appropriate construction, the sensor can determine the conductance/resistance of the liquid into which the CO2 migrates without any significant loss of accuracy arising as a result of the electropolarization of the electrodes.
For particularly high accuracy, the potential or current across the electrodes (and hence the resistance or conductance of the liquid between the electrodes) is determined using a lock-in amplifier set to the same frequency as that of the voltage generator or electrical power source.
Furthermore it is preferred to incorporate in the detection a high pass filter to screen out current with a frequency less than 100 Hz, preferably less than 150 Hz.
The filter is preferably a passive filter, for example a capacitor and a resistor.
The power source and the detector circuitry may, if desired, be included in the sensor of the invention. In this case, if it is desired that the sensor be wireless, it will preferably also be provided with means enabling the signal to be detected remotely, e.g. a transmitter, for example a RF transmitter.
A further electrode may be provided that is electrically connected to the patient, for example to the patient's skin. The signal from this fu.rther electrode may be processed with the signal from the sensor in order to compensate for electromagnetic noise from the patient.
Electropolarization effects are considerably reduced by increasing the surface area of the electrodes in contact with the liquid, e.g. by siting the electrodes in wells disposed away from the plane of the membrane or by using non-planar electrode surfaces, e.g. rough or textured surfaces. In general therefore it is desirable to have as large a ratio of surface area of electrode to liquid contact as possible, and as shallow as possible a liquid depth over as much as possible of its area of contact with the membrane. In this way the response time is reduced, electropolarization is reduced, lower frequencies may be used and stray capacitance effects are considerably reduced.
Increased electrical resistance relative to the resistance at the electrodes may be achieved by restricting the cross sectional area of the electrical path through the liquid between the electrodes at a zone in which the liquid is in contact with the membrane, e.g. by decreasing the depth of the liquid for a part of the path between the electrodes, and/or by ensuring a relatively large area of contact between each electrode and the liquid.
The resistance of the liquid at the membrane and between the electrodes may be increased by the use of structural elements to define liquid channels across the membrane between the electrodes, e.g. by disposing the membrane across or adjacent an insulating chamber wall portion in which such channels are formed, for example by etching. Likewise a porous spacer may be disposed between the membrane and the chamber wall to define the depth of the liquid.
Indeed, such spacers are important to use where, under the pressure conditions experienced in use, the membrane is sufficiently flexible and the liquid depth behind the membrane sufficiently small, for the measured conductance to vary with pressure.
In a preferred arrangement, the pCO2 sensor comprises:
a sensor body having a longitudinal axis;
at least two electrodes spaced in a direction transverse to the longitudinal axis of the sensor body;
a plurality of support members extending outwardly from the axis of the sensor body and defining between adjacent support members at least one liquid channel that provides a fluid pathway between the electrodes; and a gas-permeable membrane supported by the support members and providing an outer wall of the liquid channel(s).
This arrangement provides a compact configuration of the sensor with a longitudinal geometry that is suited to insertion in the tissue of a patient.
Furthermore, the support members are able to provide physical support to the membrane, as well as defining liquid channels of small cross-sectional area that allow accurate measurement.
In order to reduce the electropolarisation effect mentioned above, the electrodes may be located in a recess in the sensor body that has a greater cross-sectional area than the liquid channels. In this way, the current density around the electrodes is reduced by the greater volume for liquid.
The electrodes of the pCO2 sensor may extend longitudinally, for example parallel to the longitudinal axis of the sensor body.
Similarly, the liquid channel(s) may be transverse, for example perpendicular, to the longitudinal axis of the sensor body. In a preferred arrangement, the pCOZ sensor comprises a plurality of liquid channels. For example, the sensor may comprise at least three liquid channels.
The support members may be transverse to the longitudinal axis of the sensor body. For example, the support members may be perpendicular to the longitudinal axis of the sensor body in the circumferential direction. In a preferred arrangement, the support members are in the form of rings formed about the longitudinal axis of the sensor body. The cross-section of the support members may be any suitable shape. It has been found in particular that support members with a substantially triangular, in particular sawtooth, cross-section are particularly easily formed by injection moulding. Alternatively, a substantially rectangular cross-section may be used. The support members may be formed integrally with the sensor body, for example by injection moulding. The sensor preferably comprises at least four support members.
The sensor body and/or the pCO2 sensor may be generally cylindrical. The membrane may be arranged to surround the sensor body.
The described geometry may be applied to any suitable sensor. In the preferred arrangement, the sensor is a pCO2 sensor.
Where the pCO2 sensor is constructed with the liquid film in place, the electrodes are preferably of, or plated with, an inert material such that the resistivity of the liquid will not change significantly with storage. Suitable materials include platinum (especially black platinum), gold, silver, aluminium and carbon. Gold is particularly preferred. In general inert electrodes which do not generate solvated ions are preferred.
The membrane may be any material which is permeable to C02, and substantially impermeable to the solvent of the liquid, any electrolyte and water.
Polytetrafluoroethylene, e.g. Teflon , silicone rubber, polysiloxane, polyolefins or other insulating polymer films may be used, e.g. at thicknesses of 0.5 to 250 m.
The thicker the membrane, in general the slower the response time of the pCO2 sensor will be. However the thinner the membrane the greater the risk of non -uniformities or of perforation or other damage. Conveniently, however, the thickness of the membrane will be 1 to 100 m, preferably 50 to 100 gm.
The walls of the chamber of the pCO2 sensor of the invention may be of any suitable material, e.g. plastics. Preferably the material should be capable of withstanding conditions normally used in sterilisation, e.g. radiation sterilization (for example using gamma radiation) or thermal sterilization (for example using temperatures of about 121 C as used in autoclave sterilisation). In the case of thermal sterilization, the liquid will generally be sterile filled into the sensor after sterilization. The walls of the chamber and the membrane may be of the same material, e.g. Teflon , machined to have self-supporting walls and a thinner gas-permeable membrane.
The pCOa sensor of the invention is generally relatively inexpensive and so, unlike prior art sensors, may be single-use devices. Moreover the electrode chamber can be made extremely small without difficulty (unlike the prior art glass electrode containing sensors for which miniaturization poses insuperable impedance problems).
The above arrangement provides a pCO2 sensor, which can be inserted easily into the tissue of an animal, including a human, which can be retained in the tissue during monitoring and which can be removed easily when monitoring is complete.
The pCO2 sensor is sufficiently small that it will not cause undue disturbance to the tissue to be monitored. Consequently, the sensor may have a maximum diameter of 2 mm, preferably 1 mm.
The temperature sensor may be applied to the patient's skin, in use of the sensor device. However, in one enibodiment of the invention, the temperature sensor is configured for insertion through the patient's skin. In particular, the temperature sensor and the pCO2 sensor may be incorporated into a single sensor unit. In other words, the pCO2 sensor may include the temperature sensor.
Blood oxygen saturation levels may be measured by pulse oxymetry. Thus, the device may comprise a pulse oxymetry sensor. In pulse oxymetry, the saturation of oxyhaemoglobin in a patient's blood is determined by measuring the absorption of light by the haemoglobin. The degree of absorption differs depending on whether the haemoglobin is saturated or desaturated with oxygen. The blood oxygenation sensor according to the present invention may, in particular, be a reflectance pulse oxymetry sensor. In other words, the sensor may be configured to illuminate the patient's skin with light of a specified wavelength or wavelengths and measure the reflectance of these wavelengths in order to determine the degree of oxygen saturation of the patient's blood. Conveniently, therefore, the blood oxygenation sensor may be configured to be retained against the patient's skin by the adhesive patch.
The sensor device may comprise a dedicated heart rate sensor.
Conveniently, however, the oxygen saturation sensor and heart rate sensor are provided by a pulse oxymetry sensor.
The sensor device may comprise a plurality of sensors for respective physiological parameters. For example, the device may comprise an array of sensors. Such sensors may measure one or more of the partial pressure of carbon dioxide, the partial pressure of oxygen, temperature, pH or glucose concentration, for example. The sensors may be provided, for example, on the plaster or adhesive patch. In the presently preferred embodiment, the device comprises a temperature sensor, a pCO2 sensor, a heart rate sensor and a blood oxygenation sensor.
The pCO2, oxygenation and temperature determined by the sensor device may be a quantified value or may simply be an indication that the values are above or below one or more threshold values indicative of sepsis, values which may be varied according to the location of the measurement site.
The sensor device may be used for a single measurement or, more preferably, may be used for continuous or repeated monitoring, e.g. in emergency and intensive care settings or in the ward or nursing homes of any risk patient for fast detection and immediate treatment of changes in vital signs.
Although the sensor has been described in relation to the detection of sepsis, it may be used to detect any condition that will cause either hypocarbia or hypercarbia in the tissue, i.e. any condition that will either change the respiratory pattern of the patient, or conditions that will increase the production of or reduce the elimination of CO2. Conditions where hypocarbia is likely to be found include sepsis, fever of origin other than sepsis per se, moderate cardiac failure, pulmonary oedema, acute respiratory distress syndrome (ARDS) and hyperventilation of any cause. Conditions where hypercarbia is likely to be found include ischemia at the place where the sensor is located, circulatory shock of haemorrhagic, cardiac or septic origin and respiratory insufficiency, acute or chronic, such as ARDS or chronic obstructive lung disease (COLD).
An embodiment of the invention will now be described, by way of example only, with reference to the accompanying drawings, in which:
Figure 1 is a schematic diagram of a complete sensing system incorporating the sensor device of the invention;
Figure 2 is a schematic diagram illustrating the measurement principle for the pCO2 sensor in the system of Figure 1;
Figure 3 is a partially cutaway view of a pCOa sensor according to the invention;
Figure 4 is a cross-sectional view along line A-A of Figure 3;
Figure 4a is a magnified view of the detail indicated by the circle in Figure 4;
Figure 5 is a view of the pCO2 sensor of Figure 3 with the membrane removed;
Figure 6 illustrates a variant of the pCO2 sensor of Figure 3 wherein the attachment mechanism is visible;
Figure 7 is a plan view of a sensor device according to an embodiment of the invention;
Figure 8 is a side view, partially in section, of the sensor device of Figure 7;
Figure 9 is a side view of the sensor device of Figures 7 and 8 in the position of use;
Figure 10 is an enlarged view of the pCOa and temperature sensor of the sensor device of Figures 7 to 9;
Figure 11 shows a sensor device according to an alternative embodiment of the invention;
Figure 12 is a perspective view, partially in section, of the sensor device of Figure 11;
Figure 13 is a sectional view of a details of the sensor device of Figures 11 and 12;
Similarly, the liquid channel(s) may be transverse, for example perpendicular, to the longitudinal axis of the sensor body. In a preferred arrangement, the pCOZ sensor comprises a plurality of liquid channels. For example, the sensor may comprise at least three liquid channels.
The support members may be transverse to the longitudinal axis of the sensor body. For example, the support members may be perpendicular to the longitudinal axis of the sensor body in the circumferential direction. In a preferred arrangement, the support members are in the form of rings formed about the longitudinal axis of the sensor body. The cross-section of the support members may be any suitable shape. It has been found in particular that support members with a substantially triangular, in particular sawtooth, cross-section are particularly easily formed by injection moulding. Alternatively, a substantially rectangular cross-section may be used. The support members may be formed integrally with the sensor body, for example by injection moulding. The sensor preferably comprises at least four support members.
The sensor body and/or the pCO2 sensor may be generally cylindrical. The membrane may be arranged to surround the sensor body.
The described geometry may be applied to any suitable sensor. In the preferred arrangement, the sensor is a pCO2 sensor.
Where the pCO2 sensor is constructed with the liquid film in place, the electrodes are preferably of, or plated with, an inert material such that the resistivity of the liquid will not change significantly with storage. Suitable materials include platinum (especially black platinum), gold, silver, aluminium and carbon. Gold is particularly preferred. In general inert electrodes which do not generate solvated ions are preferred.
The membrane may be any material which is permeable to C02, and substantially impermeable to the solvent of the liquid, any electrolyte and water.
Polytetrafluoroethylene, e.g. Teflon , silicone rubber, polysiloxane, polyolefins or other insulating polymer films may be used, e.g. at thicknesses of 0.5 to 250 m.
The thicker the membrane, in general the slower the response time of the pCO2 sensor will be. However the thinner the membrane the greater the risk of non -uniformities or of perforation or other damage. Conveniently, however, the thickness of the membrane will be 1 to 100 m, preferably 50 to 100 gm.
The walls of the chamber of the pCO2 sensor of the invention may be of any suitable material, e.g. plastics. Preferably the material should be capable of withstanding conditions normally used in sterilisation, e.g. radiation sterilization (for example using gamma radiation) or thermal sterilization (for example using temperatures of about 121 C as used in autoclave sterilisation). In the case of thermal sterilization, the liquid will generally be sterile filled into the sensor after sterilization. The walls of the chamber and the membrane may be of the same material, e.g. Teflon , machined to have self-supporting walls and a thinner gas-permeable membrane.
The pCOa sensor of the invention is generally relatively inexpensive and so, unlike prior art sensors, may be single-use devices. Moreover the electrode chamber can be made extremely small without difficulty (unlike the prior art glass electrode containing sensors for which miniaturization poses insuperable impedance problems).
The above arrangement provides a pCO2 sensor, which can be inserted easily into the tissue of an animal, including a human, which can be retained in the tissue during monitoring and which can be removed easily when monitoring is complete.
The pCO2 sensor is sufficiently small that it will not cause undue disturbance to the tissue to be monitored. Consequently, the sensor may have a maximum diameter of 2 mm, preferably 1 mm.
The temperature sensor may be applied to the patient's skin, in use of the sensor device. However, in one enibodiment of the invention, the temperature sensor is configured for insertion through the patient's skin. In particular, the temperature sensor and the pCO2 sensor may be incorporated into a single sensor unit. In other words, the pCO2 sensor may include the temperature sensor.
Blood oxygen saturation levels may be measured by pulse oxymetry. Thus, the device may comprise a pulse oxymetry sensor. In pulse oxymetry, the saturation of oxyhaemoglobin in a patient's blood is determined by measuring the absorption of light by the haemoglobin. The degree of absorption differs depending on whether the haemoglobin is saturated or desaturated with oxygen. The blood oxygenation sensor according to the present invention may, in particular, be a reflectance pulse oxymetry sensor. In other words, the sensor may be configured to illuminate the patient's skin with light of a specified wavelength or wavelengths and measure the reflectance of these wavelengths in order to determine the degree of oxygen saturation of the patient's blood. Conveniently, therefore, the blood oxygenation sensor may be configured to be retained against the patient's skin by the adhesive patch.
The sensor device may comprise a dedicated heart rate sensor.
Conveniently, however, the oxygen saturation sensor and heart rate sensor are provided by a pulse oxymetry sensor.
The sensor device may comprise a plurality of sensors for respective physiological parameters. For example, the device may comprise an array of sensors. Such sensors may measure one or more of the partial pressure of carbon dioxide, the partial pressure of oxygen, temperature, pH or glucose concentration, for example. The sensors may be provided, for example, on the plaster or adhesive patch. In the presently preferred embodiment, the device comprises a temperature sensor, a pCO2 sensor, a heart rate sensor and a blood oxygenation sensor.
The pCO2, oxygenation and temperature determined by the sensor device may be a quantified value or may simply be an indication that the values are above or below one or more threshold values indicative of sepsis, values which may be varied according to the location of the measurement site.
The sensor device may be used for a single measurement or, more preferably, may be used for continuous or repeated monitoring, e.g. in emergency and intensive care settings or in the ward or nursing homes of any risk patient for fast detection and immediate treatment of changes in vital signs.
Although the sensor has been described in relation to the detection of sepsis, it may be used to detect any condition that will cause either hypocarbia or hypercarbia in the tissue, i.e. any condition that will either change the respiratory pattern of the patient, or conditions that will increase the production of or reduce the elimination of CO2. Conditions where hypocarbia is likely to be found include sepsis, fever of origin other than sepsis per se, moderate cardiac failure, pulmonary oedema, acute respiratory distress syndrome (ARDS) and hyperventilation of any cause. Conditions where hypercarbia is likely to be found include ischemia at the place where the sensor is located, circulatory shock of haemorrhagic, cardiac or septic origin and respiratory insufficiency, acute or chronic, such as ARDS or chronic obstructive lung disease (COLD).
An embodiment of the invention will now be described, by way of example only, with reference to the accompanying drawings, in which:
Figure 1 is a schematic diagram of a complete sensing system incorporating the sensor device of the invention;
Figure 2 is a schematic diagram illustrating the measurement principle for the pCO2 sensor in the system of Figure 1;
Figure 3 is a partially cutaway view of a pCOa sensor according to the invention;
Figure 4 is a cross-sectional view along line A-A of Figure 3;
Figure 4a is a magnified view of the detail indicated by the circle in Figure 4;
Figure 5 is a view of the pCO2 sensor of Figure 3 with the membrane removed;
Figure 6 illustrates a variant of the pCO2 sensor of Figure 3 wherein the attachment mechanism is visible;
Figure 7 is a plan view of a sensor device according to an embodiment of the invention;
Figure 8 is a side view, partially in section, of the sensor device of Figure 7;
Figure 9 is a side view of the sensor device of Figures 7 and 8 in the position of use;
Figure 10 is an enlarged view of the pCOa and temperature sensor of the sensor device of Figures 7 to 9;
Figure 11 shows a sensor device according to an alternative embodiment of the invention;
Figure 12 is a perspective view, partially in section, of the sensor device of Figure 11;
Figure 13 is a sectional view of a details of the sensor device of Figures 11 and 12;
Figure 14 is a plan view of the sensor device of Figures 11 to 13 without the insertion needle; and Figure 15 is a perspective view of the sensor device in the position of Figures 14.
In accordance with the invention, a pCO2 sensing system comprises a sensor device 50, an electronic surface unit 2, and a monitor unit 3, as shown in Figure 1.
The sensor device 50 comprises a combined pCO2 and temperature sensor unit 1 and two pulse oxymetry sensors 54.
Figures 7 to 10 show the sensor device 50 according to an embodiment of the invention. The device 50 comprises a self-adhesive strip 52 onto which are mounted two reflection pulse oxymetiy sensors 54 and a sensor unit I which will be described in detail below. The pulse oxymetry sensors may be of the type commercially available from Nellcor of Pleasanton, California as MAX FAST adhesive forehead sensors. The self-adhesive strip 52 is provided with a release strip 56 which can be peeled from the adhesive strip 52 to reveal the adhesive surface of the adhesive strip 52 for application to a patient's skin. The sensor device 50 is provided packaged with the sensor unit I in a tube (not shown) filled with a sterile aqueous isotonic solution of propylene glycol to prevent any damage, contamination or evaporation.
The sensor device 50 includes a mandrel 58 provided with a finger grip 60.
The mandrel 58 is received in a flexible sheath (or catheter) 62 which contains the cable connections 6 from the sensor unit 1. As shown in Figure 10, at its distal end, the mandrel 58 engages the sensor unit I and allows the pointed sensor unit 1 to be driven through a patient's skin by the application of manual pressure to the finger grip 60 of the mandre158. In this way, the sensor unit 1 is located in the patient's muscle, for example in the patient's underarm.
When the pCO2 sensor unit I has been located correctly in the patient's muscle, the mandrel 58 is withdrawn from the flexible sheath 621eaving the sensor device 50 in the configuration shown in Figure 9. The sheath 62 and cables 6 that are connected to the sensor unit 1 are sufficiently flexible that the patient feels little, if any, discomfort with the sensor unit 1 in position.
The sensor unit 1 is held in position in the muscle by the adhesive strip 52 adhering to the patient's skin. At the same time, the adhesion of the adhesive strip 52 to the skin brings the pulse oxymetry sensors 54 into their position of use against the patient's skin. The pulse oxymetry sensors 54 measure the reflectance of specified wavelengths of light from the patient's skin in order to determine the oxygen saturation level in the patient's blood.
As shown most clearly in Figure 7, electrical connections 64 from the pulse oxymetry sensors 54 and from the sensor unit I run longitudinally along the adhesive strip 52 for connection to the electronic surface unit 2.
Alternatively, as shown in Figure 9, the sensor device 50 may be provided with a wireless device for communication with the electronic surface unit 2 or the monitor unit 3.
The sensor device 50 is delivered packaged and sterilised. It includes a membrane-protected conductometric sensor 4 with a diameter of less than 1 millimetre, and a temperature probe 5 integrated in the sensor unit 1. Wires 6 connect the sensor 4 and probe 5 electrically by means of a connector to the electronic surface unit 2.
The electronic surface unit 2 sends and receives signals to and from the sensor device 50. It is placed on the patient's skin, performs signal processing on signals from the sensor unit I and transmits the conditioned signal to the monitor unit 5.
The monitor unit 3 is based on a portable personal computer 7 with PCMCIA
input/output card 8 and Labview software (available from National Instruments Corporation of Austin, Texas).
The pCO2 sensor 4 is used for measurements of the level (partial pressure) of CO2 (pC02) in tissue, according to the measurement principle illustrated in Figure 2.
The measurement chamber consists of two small cavities 9 with one electrode 10 positioned in each. The two cavities 9 are connected by one or more passageways 11 enclosed by a semi-permeable membrane 12, i.e. a membrane that only allows transport of COZ in and out of the volume of the sensor 4. The whole volume is filled with de-ionised water and 5% propylene glycol . The conductivity in the water depends upon the pC02, and by measuring the conductivity between the electrodes 10 in the volume, information about pC02 may be extracted.
As shown in Figures 3 to 5, the sensor unit I comprises an injection moulded plastics support 23, which is substantially cylindrical and surrounded by the semi-permeable membrane 12. The support 23 has a pointed tip 24 at its distal end and a body portion 25 which extends proximally from the tip 24. On the body portion are mounted, by gluing, two gold electrodes 10. The electrodes 10 extend longitudinally along opposed sides of the body portion 25 and are received in respective recesses in the body portion 25.
Between the tip 24 and the body portion 25, a frustoconical projection 26 is provided for securing the membrane 12 by frictional fit. A corresponding projection 26 is provided at the proximal end of the body portion 25. The membrane 12 may be glued to the support 23, but it is important that the glue used to secure the membrane 12 and electrodes 10 is selected such that it does not bleed ions into the water-filled chamber formed between the body portion 25 of the support 23 and the membrane 12. Furthermore, the sealing faces of the support 23 may be made selectively hydrophobic in order to avoid the formation of a water film into which ions may bleed.
The membrane 12 may also be secured to the support 23 by means of crimp connection and a soft gasket, if necessary. The membrane 12 may act as the gasket, particularly where the membrane 12 is formed of silicone rubber. A heat shrink sleave may be used to form the crimp connection, as is the case in Figure 6.
Alternatively, metal crimp rings may be used in locations corresponding to those of the sealing projections 26.
The body portion 25 of the support 23 is provided with a plurality of ribs 27, which are formed with a saw tooth profile for easy moulding. The ribs 28 provide mechanical support to the membrane 12 and also define the fluid passageways 11 required for the sensor 4 to function effectively. Between each electrode 10 and the fluid passageways formed between the ribs 27 is provided a reservoir 9 formed by the recess in which the electrode 10 is located. The reservoir 9 provides a region of relatively low current density around the electrodes 10 in order to reduce electropolarisation effects.
During manufacture, the membrane 12 is fixed onto the support 23, while immersed in the de-ionised water and propylene glycol solution, so that the chamber bounded by the membrane 12, the electrodes 10, and the ribs 27 is completely filled with liquid. Thus, this chamber forms a pCO2 sensor as shown schematically in Figure 2.
It is possible for the sensor 1 to include more than one sensing chamber. For example, two parallel electrodes 10 separated by a wall member may be provided on each side of the support 23. A sensing chamber is thereby formed between one electrode 10 on one side of support 23 via the fluid passageways 11 between the ribs 27 on the top of the support 23 to one of the electrodes 10 on the other side of the support 23. A corresponding sensing chamber is provided between the remaining electrodes 10 and the fluid passageways 11 on the bottom of the support 11. An electrode 10 from each of these chambers may be electrically connected to the corresponding electrode from the other chamber, such that the electrical signal from the sensor reflects the conductivity of both chambers.
Embedded in the proximal end of the support 23 is a temperature sensor 5 in the form of a thermocouple. The temperature sensor 5 is used both for pCO2 corrective calculations and for the measured tissue temperatures to be displayed on the monitor 3, which is informative for medical diagnosis. The temperature sensor 5 has a minimum measuring range of 33-42 C and a minimum accuracy of +/- 0.2 C.
A ribbon cable 6 is electrically and mechanically connected to the electrodes 10 and the temperature sensor 5. The electrodes 10 are formed as extensions of the conductors of the ribbon cable 6. Alternatively, the electrodes may be formed by plating onto the support 23. Where the cable 6 and the connection to the support 23 are sufficiently strong, the cable 6 can be used to pull the sensor unit I
from its position of use. Alternatively, a Kevlar line may be provided, for example incorporated with the ribbon cable 6, to provide a strong external mechanical connection.
The membrane 12 may extend proximally from the support 23 with the cable 6 to form a catheter around the cable 6. Alternatively, a separate catheter 28 may be provided. In this case, the catheter 28 is bonded to the support 23 proximally of the electrodes 10 and the membrane 12.
As shown in Figure 6, the catheter 28 may be provided with a plurality of slits 29 in order to fix the sensor unit 1 in position in tissue. The slits 29 are arranged such that when the catheter 28 is pushed distally (in the direction of the arrow B in Figure 6), relative to the cable 6 (or Kevlar line) the portions 30 of the catheter 28 between the slits 29 are forced outwardly and assume the shape shown in phantom in Figure 6. The radially projecting portions 30 of the catheter 28 retain the sensor unit 1 in the tissue in which it is embedded. The relative position of the catheter 28 and the cable 6 can be maintained with a locking mechanism (not shown) until it is time for the sensor unit 1 to be removed from the tissue.
At this time, the locking mechanism can be released and the portions 30 of the catheter 28 will return to their relaxed position so that the sensor unit 1 can be removed from the tissue.
The catheter tip with the integrated sensor 4 is placed 0.5 - 4 cm into tissue to measure pCO2 to detect and monitor the effect of treatment of the diseases and conditions mentioned above during a period of up to four weeks.
The sensor unit 1 has a maximum diameter of 1 mm and the maximum distance from the catheter tip to the sensor element is 2 mm. The sensor 4 has a minimum pCO2 measuring range of 2-25 kPa, with a minimum detectable pCO2 difference of 0.2 kPa. The maximum response of the sensor 4 is 20 seconds. The maximum allowable measurement current is in any area of the fluid chamber is such that j<1mA/cma while the measuring input voltage is not more than 50 mV RMS.
The electrodes 10 are gold plated and their total area is approximately 0.3 mma. The measurement frequency fineas should be higher than 100 Hz. At lower frequencies, polarisation effects in the measurement chamber dominate the measurements. At frequencies above 10 kHz, the low impedance of the capacitances become a significant issue. The measurement resistance R measure is in the range of 500 kOhm to 7 MOhm.
The sensor 4 is electrically connected to an electronic surface unit 2 located on the patient skin by the ribbon cable 6, which has a length between 5 cm and metre. The maximum diameter of the cable/catheter is 1 mm. The cable/catheter is soft and flexible so that it does not excessively disturb the neighbouring tissue. The cable/catheter and its connections are also sufficiently robust to withstand any pulling forces which may be caused by both normal and "abnormal" use.
In accordance with the invention, a pCO2 sensing system comprises a sensor device 50, an electronic surface unit 2, and a monitor unit 3, as shown in Figure 1.
The sensor device 50 comprises a combined pCO2 and temperature sensor unit 1 and two pulse oxymetry sensors 54.
Figures 7 to 10 show the sensor device 50 according to an embodiment of the invention. The device 50 comprises a self-adhesive strip 52 onto which are mounted two reflection pulse oxymetiy sensors 54 and a sensor unit I which will be described in detail below. The pulse oxymetry sensors may be of the type commercially available from Nellcor of Pleasanton, California as MAX FAST adhesive forehead sensors. The self-adhesive strip 52 is provided with a release strip 56 which can be peeled from the adhesive strip 52 to reveal the adhesive surface of the adhesive strip 52 for application to a patient's skin. The sensor device 50 is provided packaged with the sensor unit I in a tube (not shown) filled with a sterile aqueous isotonic solution of propylene glycol to prevent any damage, contamination or evaporation.
The sensor device 50 includes a mandrel 58 provided with a finger grip 60.
The mandrel 58 is received in a flexible sheath (or catheter) 62 which contains the cable connections 6 from the sensor unit 1. As shown in Figure 10, at its distal end, the mandrel 58 engages the sensor unit I and allows the pointed sensor unit 1 to be driven through a patient's skin by the application of manual pressure to the finger grip 60 of the mandre158. In this way, the sensor unit 1 is located in the patient's muscle, for example in the patient's underarm.
When the pCO2 sensor unit I has been located correctly in the patient's muscle, the mandrel 58 is withdrawn from the flexible sheath 621eaving the sensor device 50 in the configuration shown in Figure 9. The sheath 62 and cables 6 that are connected to the sensor unit 1 are sufficiently flexible that the patient feels little, if any, discomfort with the sensor unit 1 in position.
The sensor unit 1 is held in position in the muscle by the adhesive strip 52 adhering to the patient's skin. At the same time, the adhesion of the adhesive strip 52 to the skin brings the pulse oxymetry sensors 54 into their position of use against the patient's skin. The pulse oxymetry sensors 54 measure the reflectance of specified wavelengths of light from the patient's skin in order to determine the oxygen saturation level in the patient's blood.
As shown most clearly in Figure 7, electrical connections 64 from the pulse oxymetry sensors 54 and from the sensor unit I run longitudinally along the adhesive strip 52 for connection to the electronic surface unit 2.
Alternatively, as shown in Figure 9, the sensor device 50 may be provided with a wireless device for communication with the electronic surface unit 2 or the monitor unit 3.
The sensor device 50 is delivered packaged and sterilised. It includes a membrane-protected conductometric sensor 4 with a diameter of less than 1 millimetre, and a temperature probe 5 integrated in the sensor unit 1. Wires 6 connect the sensor 4 and probe 5 electrically by means of a connector to the electronic surface unit 2.
The electronic surface unit 2 sends and receives signals to and from the sensor device 50. It is placed on the patient's skin, performs signal processing on signals from the sensor unit I and transmits the conditioned signal to the monitor unit 5.
The monitor unit 3 is based on a portable personal computer 7 with PCMCIA
input/output card 8 and Labview software (available from National Instruments Corporation of Austin, Texas).
The pCO2 sensor 4 is used for measurements of the level (partial pressure) of CO2 (pC02) in tissue, according to the measurement principle illustrated in Figure 2.
The measurement chamber consists of two small cavities 9 with one electrode 10 positioned in each. The two cavities 9 are connected by one or more passageways 11 enclosed by a semi-permeable membrane 12, i.e. a membrane that only allows transport of COZ in and out of the volume of the sensor 4. The whole volume is filled with de-ionised water and 5% propylene glycol . The conductivity in the water depends upon the pC02, and by measuring the conductivity between the electrodes 10 in the volume, information about pC02 may be extracted.
As shown in Figures 3 to 5, the sensor unit I comprises an injection moulded plastics support 23, which is substantially cylindrical and surrounded by the semi-permeable membrane 12. The support 23 has a pointed tip 24 at its distal end and a body portion 25 which extends proximally from the tip 24. On the body portion are mounted, by gluing, two gold electrodes 10. The electrodes 10 extend longitudinally along opposed sides of the body portion 25 and are received in respective recesses in the body portion 25.
Between the tip 24 and the body portion 25, a frustoconical projection 26 is provided for securing the membrane 12 by frictional fit. A corresponding projection 26 is provided at the proximal end of the body portion 25. The membrane 12 may be glued to the support 23, but it is important that the glue used to secure the membrane 12 and electrodes 10 is selected such that it does not bleed ions into the water-filled chamber formed between the body portion 25 of the support 23 and the membrane 12. Furthermore, the sealing faces of the support 23 may be made selectively hydrophobic in order to avoid the formation of a water film into which ions may bleed.
The membrane 12 may also be secured to the support 23 by means of crimp connection and a soft gasket, if necessary. The membrane 12 may act as the gasket, particularly where the membrane 12 is formed of silicone rubber. A heat shrink sleave may be used to form the crimp connection, as is the case in Figure 6.
Alternatively, metal crimp rings may be used in locations corresponding to those of the sealing projections 26.
The body portion 25 of the support 23 is provided with a plurality of ribs 27, which are formed with a saw tooth profile for easy moulding. The ribs 28 provide mechanical support to the membrane 12 and also define the fluid passageways 11 required for the sensor 4 to function effectively. Between each electrode 10 and the fluid passageways formed between the ribs 27 is provided a reservoir 9 formed by the recess in which the electrode 10 is located. The reservoir 9 provides a region of relatively low current density around the electrodes 10 in order to reduce electropolarisation effects.
During manufacture, the membrane 12 is fixed onto the support 23, while immersed in the de-ionised water and propylene glycol solution, so that the chamber bounded by the membrane 12, the electrodes 10, and the ribs 27 is completely filled with liquid. Thus, this chamber forms a pCO2 sensor as shown schematically in Figure 2.
It is possible for the sensor 1 to include more than one sensing chamber. For example, two parallel electrodes 10 separated by a wall member may be provided on each side of the support 23. A sensing chamber is thereby formed between one electrode 10 on one side of support 23 via the fluid passageways 11 between the ribs 27 on the top of the support 23 to one of the electrodes 10 on the other side of the support 23. A corresponding sensing chamber is provided between the remaining electrodes 10 and the fluid passageways 11 on the bottom of the support 11. An electrode 10 from each of these chambers may be electrically connected to the corresponding electrode from the other chamber, such that the electrical signal from the sensor reflects the conductivity of both chambers.
Embedded in the proximal end of the support 23 is a temperature sensor 5 in the form of a thermocouple. The temperature sensor 5 is used both for pCO2 corrective calculations and for the measured tissue temperatures to be displayed on the monitor 3, which is informative for medical diagnosis. The temperature sensor 5 has a minimum measuring range of 33-42 C and a minimum accuracy of +/- 0.2 C.
A ribbon cable 6 is electrically and mechanically connected to the electrodes 10 and the temperature sensor 5. The electrodes 10 are formed as extensions of the conductors of the ribbon cable 6. Alternatively, the electrodes may be formed by plating onto the support 23. Where the cable 6 and the connection to the support 23 are sufficiently strong, the cable 6 can be used to pull the sensor unit I
from its position of use. Alternatively, a Kevlar line may be provided, for example incorporated with the ribbon cable 6, to provide a strong external mechanical connection.
The membrane 12 may extend proximally from the support 23 with the cable 6 to form a catheter around the cable 6. Alternatively, a separate catheter 28 may be provided. In this case, the catheter 28 is bonded to the support 23 proximally of the electrodes 10 and the membrane 12.
As shown in Figure 6, the catheter 28 may be provided with a plurality of slits 29 in order to fix the sensor unit 1 in position in tissue. The slits 29 are arranged such that when the catheter 28 is pushed distally (in the direction of the arrow B in Figure 6), relative to the cable 6 (or Kevlar line) the portions 30 of the catheter 28 between the slits 29 are forced outwardly and assume the shape shown in phantom in Figure 6. The radially projecting portions 30 of the catheter 28 retain the sensor unit 1 in the tissue in which it is embedded. The relative position of the catheter 28 and the cable 6 can be maintained with a locking mechanism (not shown) until it is time for the sensor unit 1 to be removed from the tissue.
At this time, the locking mechanism can be released and the portions 30 of the catheter 28 will return to their relaxed position so that the sensor unit 1 can be removed from the tissue.
The catheter tip with the integrated sensor 4 is placed 0.5 - 4 cm into tissue to measure pCO2 to detect and monitor the effect of treatment of the diseases and conditions mentioned above during a period of up to four weeks.
The sensor unit 1 has a maximum diameter of 1 mm and the maximum distance from the catheter tip to the sensor element is 2 mm. The sensor 4 has a minimum pCO2 measuring range of 2-25 kPa, with a minimum detectable pCO2 difference of 0.2 kPa. The maximum response of the sensor 4 is 20 seconds. The maximum allowable measurement current is in any area of the fluid chamber is such that j<1mA/cma while the measuring input voltage is not more than 50 mV RMS.
The electrodes 10 are gold plated and their total area is approximately 0.3 mma. The measurement frequency fineas should be higher than 100 Hz. At lower frequencies, polarisation effects in the measurement chamber dominate the measurements. At frequencies above 10 kHz, the low impedance of the capacitances become a significant issue. The measurement resistance R measure is in the range of 500 kOhm to 7 MOhm.
The sensor 4 is electrically connected to an electronic surface unit 2 located on the patient skin by the ribbon cable 6, which has a length between 5 cm and metre. The maximum diameter of the cable/catheter is 1 mm. The cable/catheter is soft and flexible so that it does not excessively disturb the neighbouring tissue. The cable/catheter and its connections are also sufficiently robust to withstand any pulling forces which may be caused by both normal and "abnormal" use.
During sterilisation, storage and transport the sensor unit I is covered by deionised, sterile and endotoxin-free water to make sure that there is substantially no net loss of water from the sensor reservoir.
Figures 11 to 15 show a sensor device 50 according to an alternative embodiment of the invention. Except where otherwise indicated, the configuration of this embodiment is the same as that of the sensor device described in relation to Figures 7 to 10. As in the previous embodiment, the device 50 comprises a self-adhesive strip 52 onto which are mounted two reflection pulse oxymetry sensors and a sensor unit 1 as described above. The self-adhesive strip 52 is provided with a release strip 56 which can be peeled from the adhesive strip 52 to reveal the adhesive surface of the adhesive strip 52 for application to a patient's skin.
The sensor device 50 is provided packaged with the sensor unit 1 in a sterile water- filled tube 72 filled with a sterile aqueous isotonic solution of propylene glycol to prevent any damage, contamination or evaporation.
The sensor device 50 includes a U-section insertion needle 74 provided with a finger grip 60. In the packaged sensor device 50, the sensor unit 1 and the associated cable connections are received in the U-shaped channel in the insertion needle 74. With the protective tube 72 removed, the insertion needle 74 can be driven through a patient's skin by the application of manual pressure to the finger grip 60. The insertion needle 74 can then be removed from the sensor device 50 leaving the sensor unit 1 located in the patient's muscle in the general configuration shown in Figure 14. The U-shape of the insertion needle 74 allows the needle to be disengaged from the cable connections 6 to the sensor unit 1 as it is withdrawn.
Figure 13 shows the detail of the connections between the insertion needle 74 and the sensor device 50. As shown in Figure 13, the U-section insertion needle 74 is moulded into the finger grip 60. The sensor device 50 is provided with a plastic housing 76 which is located over and engages with an orifice defined in the self-adhesive strip 52. The plastic housing 76 is bonded to the self-adhesive strip 52. In the centre of the plastic housing 76 is defined a hole through which the insertion needle 74 passes. Above the hole in the plastic housing 76 a metal guide 78 in the form of a disc with a central hole for the insertion needle 74 is bonded to the plastic housing 76. The central hole in the metal guide 78 has a U-shape corresponding to the cross-section of the insertion needle 74 and acts to hold the needle 74 in position so that it cannot rotate and cause damage to the cable connections 6 to the sensor unit 1. The cable connections 6 from the sensor unit I
pass from the insertion needle 74 between the metal guide 78 and the plastic housing 76 and are surrounded by a protective sheath 62 which is glued to the metal guide 78. The holes through the metal guide 78 and the plastic housing 76 are closed by a silicone membrane 80 provided over the metal guide and through which the insertion needle 74 passes. The silicone membrane 80 elastically deforms to seal the holes when the insertion needle 74 is removed.
As shown in Figure 13, a beaded rim 82 of the cover tube 72 snap fits into a corresponding recess in the plastic housing 76 to seal the tube 72 to the sensor device 50. The tube 72 is removed from the sensor device 50 to expose the insertion needle 74 when the sensor unit 1 is to be inserted in the patient's muscle.
As shown in Figures 1 and 2, the electronic surface unit 2 comprises a sine generator 13 which provides a voltage of at least 5 Volts and a current supply of 50mV, and is powered by batteries 14. A filter 15 is provided for filtering or averaging the input of the lock-in amplifier 16. A passive filter can be used which reduces the current consumption. A pre-amplifier 17 is combined with a servo mechanism to remove DC current from the signal to reduce electrolysis effects.
According to the servo arrangement, the output of the pre-amplifier is fed back to its input via a low pass filter. Thus, only DC components of the output are fed back and cancel any DC current drawn through the pCO2 sensor. In this way, it is ensured that there is no DC current through the pCO2 sensor which would degrade the electrodes. The op-atnp used in this stage consumes minimal current and has a large CMMR value. At the same time, the bias current is minimal. A lock-in amplifier amplifies the AC signal from the sensor 4. This may be built with op-amps or using an IC package with at least 1% accuracy for the signal detection at frequencies lower than 1kHz. A galvanic division 19 such as an optocoupler or a coil coupler is provided to prevent noise transfer from the monitor unit 3 and associated cabling 18.
The optocoupler is normally favoured due to the noise signal ratio. A
temperature signal amplification and conditioning unit 20 is provided to amplify the signal from the temperature sensor 5. The electronic unit 2 is powered by a rechargeable and changeable standard type battery 14. The battery capacity is sufficient for 14 days continuous monitoring. The surface unit 2 is also provided with an on/off indicator LED 21, and a battery status indicator (not shown). Conununication between the surface unit 2 and the monitor 3 is analogue through a shielded cable 18.
However, the surface unit 2 may include an analogue to digital converter such that communication between the surface unit 2 and the monitor 3 may be digital, for example by digital wire transmission or digital wireless transmission. The cable 18 is at least 4 m long and light and flexible.
As shown in Figures 1 and 2, an AC current is generated by sine generator 13 and fed to one of the pCO2 sensor electrodes 10 and to a lock-in amplifier 16.
The high-pass signal from the other pCO2 electrode 10 is passed through a filter 15 to a low noise amplifier 17 and from there to the lock-in amplifier 16 where it is compared to the reference signal generated by the sine generator 13. Out of phase components, i.e. undesired components, of the signal are rejected and the remaining portion of the signal is amplified. The amplified signal is proportional to pCO2 (or conductance) and is passed on for recordal or further manipulation to the monitor 3.
The surface unit 2 may also be electrically connected to a reference electrode (not shown) that is electrically connected to the patient's skin. The signal from the reference electrode can be used to compensate the signals from the sensor unit 1 for the effect of electromagnetic noise generated by the patient.
A single surface unit 2 may receive signals from several sensor units 1 and provide a multiplexed output to the monitor unit 3.
The monitor unit 3 comprises a portable PC 7 including CD RW and IR port, and a PCMCIA UO card 8 which can collect signals from at least 4 different surface units 2 simultaneously. The PCMCIA card 8 may have an integrated non-galvanic coupling. The power supply 22 for the monitor unit 3 is of a medically approved type operating on both 11 OV and 230V.
The software functions of the monitor unit 3 may be implemented in Labview, a software package available from National Instruments of Austin, Texas and capable of handling up to 4 different surface units simultaneously. The software provides the facility for calibration of the sensor(s) with three calibration points and a second order calibration function. The software can be modified to support any other number of calibration points and type of calibration function. The software also has the facility to smooth the signal from the sensor device 50 over defined time intervals. It is possible to have at least two alarm levels for the measurement values and two alarm levels for their gradients. The measurement value gradients are calculated for individually defined time intervals. The alarm is both visible and audible. It is possible to stop an alarm indication while keeping the other alarms active. The monitor 3 can log all measured values, parameter settings and alarms throughout a session. With a 30 second logging interval there should be a storage capacity for at least 10 two week sessions on the hard disc. The session log can be saved to a writeable CD in a format readably by Microsoft Excel.
The sensor device 50 according to this embodiment of the invention is able to provide, in a single device, measurement of pC02, temperature and blood oxygenation of the patient's muscle. With this information, a physician can identify, amongst other conditions, the onset of sepsis in the patient quickly and accurately.
Although the sensor device has been described herein with particular reference to the measurement of pCO2, the general configuration of the sensor device may be used for other physiological sensors, for example body temperature, partial pressure of oxygen, pH or glucose concentration.
Figures 11 to 15 show a sensor device 50 according to an alternative embodiment of the invention. Except where otherwise indicated, the configuration of this embodiment is the same as that of the sensor device described in relation to Figures 7 to 10. As in the previous embodiment, the device 50 comprises a self-adhesive strip 52 onto which are mounted two reflection pulse oxymetry sensors and a sensor unit 1 as described above. The self-adhesive strip 52 is provided with a release strip 56 which can be peeled from the adhesive strip 52 to reveal the adhesive surface of the adhesive strip 52 for application to a patient's skin.
The sensor device 50 is provided packaged with the sensor unit 1 in a sterile water- filled tube 72 filled with a sterile aqueous isotonic solution of propylene glycol to prevent any damage, contamination or evaporation.
The sensor device 50 includes a U-section insertion needle 74 provided with a finger grip 60. In the packaged sensor device 50, the sensor unit 1 and the associated cable connections are received in the U-shaped channel in the insertion needle 74. With the protective tube 72 removed, the insertion needle 74 can be driven through a patient's skin by the application of manual pressure to the finger grip 60. The insertion needle 74 can then be removed from the sensor device 50 leaving the sensor unit 1 located in the patient's muscle in the general configuration shown in Figure 14. The U-shape of the insertion needle 74 allows the needle to be disengaged from the cable connections 6 to the sensor unit 1 as it is withdrawn.
Figure 13 shows the detail of the connections between the insertion needle 74 and the sensor device 50. As shown in Figure 13, the U-section insertion needle 74 is moulded into the finger grip 60. The sensor device 50 is provided with a plastic housing 76 which is located over and engages with an orifice defined in the self-adhesive strip 52. The plastic housing 76 is bonded to the self-adhesive strip 52. In the centre of the plastic housing 76 is defined a hole through which the insertion needle 74 passes. Above the hole in the plastic housing 76 a metal guide 78 in the form of a disc with a central hole for the insertion needle 74 is bonded to the plastic housing 76. The central hole in the metal guide 78 has a U-shape corresponding to the cross-section of the insertion needle 74 and acts to hold the needle 74 in position so that it cannot rotate and cause damage to the cable connections 6 to the sensor unit 1. The cable connections 6 from the sensor unit I
pass from the insertion needle 74 between the metal guide 78 and the plastic housing 76 and are surrounded by a protective sheath 62 which is glued to the metal guide 78. The holes through the metal guide 78 and the plastic housing 76 are closed by a silicone membrane 80 provided over the metal guide and through which the insertion needle 74 passes. The silicone membrane 80 elastically deforms to seal the holes when the insertion needle 74 is removed.
As shown in Figure 13, a beaded rim 82 of the cover tube 72 snap fits into a corresponding recess in the plastic housing 76 to seal the tube 72 to the sensor device 50. The tube 72 is removed from the sensor device 50 to expose the insertion needle 74 when the sensor unit 1 is to be inserted in the patient's muscle.
As shown in Figures 1 and 2, the electronic surface unit 2 comprises a sine generator 13 which provides a voltage of at least 5 Volts and a current supply of 50mV, and is powered by batteries 14. A filter 15 is provided for filtering or averaging the input of the lock-in amplifier 16. A passive filter can be used which reduces the current consumption. A pre-amplifier 17 is combined with a servo mechanism to remove DC current from the signal to reduce electrolysis effects.
According to the servo arrangement, the output of the pre-amplifier is fed back to its input via a low pass filter. Thus, only DC components of the output are fed back and cancel any DC current drawn through the pCO2 sensor. In this way, it is ensured that there is no DC current through the pCO2 sensor which would degrade the electrodes. The op-atnp used in this stage consumes minimal current and has a large CMMR value. At the same time, the bias current is minimal. A lock-in amplifier amplifies the AC signal from the sensor 4. This may be built with op-amps or using an IC package with at least 1% accuracy for the signal detection at frequencies lower than 1kHz. A galvanic division 19 such as an optocoupler or a coil coupler is provided to prevent noise transfer from the monitor unit 3 and associated cabling 18.
The optocoupler is normally favoured due to the noise signal ratio. A
temperature signal amplification and conditioning unit 20 is provided to amplify the signal from the temperature sensor 5. The electronic unit 2 is powered by a rechargeable and changeable standard type battery 14. The battery capacity is sufficient for 14 days continuous monitoring. The surface unit 2 is also provided with an on/off indicator LED 21, and a battery status indicator (not shown). Conununication between the surface unit 2 and the monitor 3 is analogue through a shielded cable 18.
However, the surface unit 2 may include an analogue to digital converter such that communication between the surface unit 2 and the monitor 3 may be digital, for example by digital wire transmission or digital wireless transmission. The cable 18 is at least 4 m long and light and flexible.
As shown in Figures 1 and 2, an AC current is generated by sine generator 13 and fed to one of the pCO2 sensor electrodes 10 and to a lock-in amplifier 16.
The high-pass signal from the other pCO2 electrode 10 is passed through a filter 15 to a low noise amplifier 17 and from there to the lock-in amplifier 16 where it is compared to the reference signal generated by the sine generator 13. Out of phase components, i.e. undesired components, of the signal are rejected and the remaining portion of the signal is amplified. The amplified signal is proportional to pCO2 (or conductance) and is passed on for recordal or further manipulation to the monitor 3.
The surface unit 2 may also be electrically connected to a reference electrode (not shown) that is electrically connected to the patient's skin. The signal from the reference electrode can be used to compensate the signals from the sensor unit 1 for the effect of electromagnetic noise generated by the patient.
A single surface unit 2 may receive signals from several sensor units 1 and provide a multiplexed output to the monitor unit 3.
The monitor unit 3 comprises a portable PC 7 including CD RW and IR port, and a PCMCIA UO card 8 which can collect signals from at least 4 different surface units 2 simultaneously. The PCMCIA card 8 may have an integrated non-galvanic coupling. The power supply 22 for the monitor unit 3 is of a medically approved type operating on both 11 OV and 230V.
The software functions of the monitor unit 3 may be implemented in Labview, a software package available from National Instruments of Austin, Texas and capable of handling up to 4 different surface units simultaneously. The software provides the facility for calibration of the sensor(s) with three calibration points and a second order calibration function. The software can be modified to support any other number of calibration points and type of calibration function. The software also has the facility to smooth the signal from the sensor device 50 over defined time intervals. It is possible to have at least two alarm levels for the measurement values and two alarm levels for their gradients. The measurement value gradients are calculated for individually defined time intervals. The alarm is both visible and audible. It is possible to stop an alarm indication while keeping the other alarms active. The monitor 3 can log all measured values, parameter settings and alarms throughout a session. With a 30 second logging interval there should be a storage capacity for at least 10 two week sessions on the hard disc. The session log can be saved to a writeable CD in a format readably by Microsoft Excel.
The sensor device 50 according to this embodiment of the invention is able to provide, in a single device, measurement of pC02, temperature and blood oxygenation of the patient's muscle. With this information, a physician can identify, amongst other conditions, the onset of sepsis in the patient quickly and accurately.
Although the sensor device has been described herein with particular reference to the measurement of pCO2, the general configuration of the sensor device may be used for other physiological sensors, for example body temperature, partial pressure of oxygen, pH or glucose concentration.
Claims (12)
1. A physiological sensing device comprising in combination:
a sensor for the measurement of the partial pressure of carbon dioxide (pCO2);
a body temperature sensor;
a heart rate sensor; and an oxygen saturation sensor.
a sensor for the measurement of the partial pressure of carbon dioxide (pCO2);
a body temperature sensor;
a heart rate sensor; and an oxygen saturation sensor.
2. A sensing device as claimed in claim 1, wherein the pCO2 sensor is configured for insertion through a patient's skin.
3. A sensing device as claimed in claim 1 or 2, wherein the temperature sensor is configured for insertion through a patient's skin.
4. A sensing device as claimed in any preceding claim, wherein the temperature sensor and the pCO2 sensor are provided by a sensor unit for insertion through a patient's skin.
5. A sensing device as claimed in any of claims 2 to 4 wherein the device comprises a sharp tip for puncturing a patient's skin on insertion of the pCO2 sensor.
6. A physiological sensing device comprising a pCO2 sensor configured for insertion through a patient's skin and a sharp tip for puncturing a patient's skin on insertion of the pCO2 sensor.
7. A sensing device as claimed in claim 5 or 6, wherein the sharp tip is provided by a removable hollow needle in which the pCO2 sensor is located for insertion through a patient's skin.
8. A sensing device as claimed in any preceding claim, wherein the oxygen saturation sensor is configured for application to the surface of a patient's skin.
9. A sensing device as claimed in claim 8, wherein the heart rate sensor and the oxygen saturation sensor are provided by a pulse oxymetry sensor.
10. A sensing device as claimed in any preceding claim comprising an adhesive patch for adhering the device to a patient's skin.
11. A physiological sensing device comprising a pCO2 sensor configured for insertion through a patient's skin and an adhesive patch for adhering the device to a patient's skin to retain the inserted pCO2 sensor in position.
12. A sensing device as claimed in any preceding claim, wherein the pCO2 sensor comprises a chamber bounded, at least in part, by a carbon dioxide permeable membrane and containing a substantially electrolyte-free liquid and at least two electrodes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0419958A GB0419958D0 (en) | 2003-10-20 | 2004-09-08 | Sensor |
GB0419958.4 | 2004-09-08 | ||
PCT/GB2005/003461 WO2006027586A1 (en) | 2004-09-08 | 2005-09-08 | Sensor |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2578078A1 true CA2578078A1 (en) | 2006-03-16 |
Family
ID=35207357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002578078A Abandoned CA2578078A1 (en) | 2004-09-08 | 2005-09-08 | Sensor |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1788933A1 (en) |
JP (1) | JP2008512162A (en) |
KR (1) | KR20070052781A (en) |
CN (1) | CN101026996A (en) |
AU (1) | AU2005281502A1 (en) |
BR (1) | BRPI0514953A (en) |
CA (1) | CA2578078A1 (en) |
NO (1) | NO20071363L (en) |
WO (1) | WO2006027586A1 (en) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8912908B2 (en) | 2005-04-28 | 2014-12-16 | Proteus Digital Health, Inc. | Communication system with remote activation |
US8836513B2 (en) | 2006-04-28 | 2014-09-16 | Proteus Digital Health, Inc. | Communication system incorporated in an ingestible product |
US8802183B2 (en) | 2005-04-28 | 2014-08-12 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
WO2006116718A2 (en) | 2005-04-28 | 2006-11-02 | Proteus Biomedical, Inc. | Pharma-informatics system |
US8730031B2 (en) | 2005-04-28 | 2014-05-20 | Proteus Digital Health, Inc. | Communication system using an implantable device |
US9198608B2 (en) | 2005-04-28 | 2015-12-01 | Proteus Digital Health, Inc. | Communication system incorporated in a container |
US8547248B2 (en) | 2005-09-01 | 2013-10-01 | Proteus Digital Health, Inc. | Implantable zero-wire communications system |
CN101496042A (en) | 2006-05-02 | 2009-07-29 | 普罗秋斯生物医学公司 | Patient customized therapeutic regimens |
WO2008066617A2 (en) | 2006-10-17 | 2008-06-05 | Proteus Biomedical, Inc. | Low voltage oscillator for medical devices |
EP2083680B1 (en) | 2006-10-25 | 2016-08-10 | Proteus Digital Health, Inc. | Controlled activation ingestible identifier |
EP2069004A4 (en) | 2006-11-20 | 2014-07-09 | Proteus Digital Health Inc | Active signal processing personal health signal receivers |
ES2930588T3 (en) | 2007-02-01 | 2022-12-19 | Otsuka Pharma Co Ltd | Ingestible Event Marker Systems |
MY154556A (en) | 2007-02-14 | 2015-06-30 | Proteus Digital Health Inc | In-body power source having high surface area electrode |
EP2124725A1 (en) | 2007-03-09 | 2009-12-02 | Proteus Biomedical, Inc. | In-body device having a multi-directional transmitter |
US9270025B2 (en) | 2007-03-09 | 2016-02-23 | Proteus Digital Health, Inc. | In-body device having deployable antenna |
US8115618B2 (en) | 2007-05-24 | 2012-02-14 | Proteus Biomedical, Inc. | RFID antenna for in-body device |
EP4011289A1 (en) | 2007-09-25 | 2022-06-15 | Otsuka Pharmaceutical Co., Ltd. | In-body device with virtual dipole signal amplification |
EP2268261B1 (en) | 2008-03-05 | 2017-05-10 | Proteus Digital Health, Inc. | Multi-mode communication ingestible event markers and systems, and methods of using the same |
CA3039236C (en) | 2008-07-08 | 2022-05-17 | Proteus Digital Health, Inc. | Ingestible event marker data framework |
CN102176862B (en) | 2008-08-13 | 2014-10-22 | 普罗透斯数字保健公司 | Ingestible circuitry |
JP5411943B2 (en) | 2008-11-13 | 2014-02-12 | プロテウス デジタル ヘルス, インコーポレイテッド | Ingestible therapy activation system and method |
JP2012511961A (en) | 2008-12-11 | 2012-05-31 | プロテウス バイオメディカル インコーポレイテッド | Judgment of digestive tract function using portable visceral electrical recording system and method using the same |
US9439566B2 (en) | 2008-12-15 | 2016-09-13 | Proteus Digital Health, Inc. | Re-wearable wireless device |
US9659423B2 (en) | 2008-12-15 | 2017-05-23 | Proteus Digital Health, Inc. | Personal authentication apparatus system and method |
TWI424832B (en) | 2008-12-15 | 2014-02-01 | Proteus Digital Health Inc | Body-associated receiver and method |
EP2361380B1 (en) * | 2008-12-22 | 2015-02-18 | Radiometer Medical ApS | Planar sensor |
JP5785097B2 (en) | 2009-01-06 | 2015-09-24 | プロテウス デジタル ヘルス, インコーポレイテッド | Pharmaceutical dosage delivery system |
WO2010080843A2 (en) | 2009-01-06 | 2010-07-15 | Proteus Biomedical, Inc. | Ingestion-related biofeedback and personalized medical therapy method and system |
US9041541B2 (en) | 2010-01-28 | 2015-05-26 | Seventh Sense Biosystems, Inc. | Monitoring or feedback systems and methods |
EP2408369A1 (en) | 2009-03-02 | 2012-01-25 | Seventh Sense Biosystems, Inc. | Devices and methods for the analysis of an extractable medium |
WO2010101625A2 (en) * | 2009-03-02 | 2010-09-10 | Seventh Sense Biosystems, Inc. | Oxygen sensor |
GB2480965B (en) | 2009-03-25 | 2014-10-08 | Proteus Digital Health Inc | Probablistic pharmacokinetic and pharmacodynamic modeling |
BRPI1015298A2 (en) | 2009-04-28 | 2018-05-22 | Proteus Biomedical Inc | highly reliable ingestible event markers and methods for using them |
US9149423B2 (en) | 2009-05-12 | 2015-10-06 | Proteus Digital Health, Inc. | Ingestible event markers comprising an ingestible component |
WO2011022732A2 (en) | 2009-08-21 | 2011-02-24 | Proteus Biomedical, Inc. | Apparatus and method for measuring biochemical parameters |
TWI517050B (en) | 2009-11-04 | 2016-01-11 | 普羅托斯數位健康公司 | System for supply chain management |
UA109424C2 (en) | 2009-12-02 | 2015-08-25 | PHARMACEUTICAL PRODUCT, PHARMACEUTICAL TABLE WITH ELECTRONIC MARKER AND METHOD OF MANUFACTURING PHARMACEUTICAL TABLETS | |
AU2011210648B2 (en) | 2010-02-01 | 2014-10-16 | Otsuka Pharmaceutical Co., Ltd. | Data gathering system |
CA2795746C (en) | 2010-04-07 | 2019-10-01 | Timothy Robertson | Miniature ingestible device |
TWI557672B (en) | 2010-05-19 | 2016-11-11 | 波提亞斯數位康健公司 | Computer system and computer-implemented method to track medication from manufacturer to a patient, apparatus and method for confirming delivery of medication to a patient, patient interface device |
CN101822859B (en) * | 2010-06-08 | 2012-03-07 | 中国人民解放军军事医学科学院卫生装备研究所 | Closed loop control device for low blood volume shock liquid resuscitation |
US9125625B2 (en) | 2010-06-10 | 2015-09-08 | The Regents Of The University Of California | Textile-based printable electrodes for electrochemical sensing |
WO2011163347A2 (en) | 2010-06-23 | 2011-12-29 | Seventh Sense Biosystems, Inc. | Sampling devices and methods involving relatively little pain |
US20120016308A1 (en) | 2010-07-16 | 2012-01-19 | Seventh Sense Biosystems, Inc. | Low-pressure packaging for fluid devices |
US20120039809A1 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
EP2992827B1 (en) | 2010-11-09 | 2017-04-19 | Seventh Sense Biosystems, Inc. | Systems and interfaces for blood sampling |
US9107806B2 (en) | 2010-11-22 | 2015-08-18 | Proteus Digital Health, Inc. | Ingestible device with pharmaceutical product |
WO2012125425A2 (en) | 2011-03-11 | 2012-09-20 | Proteus Biomedical, Inc. | Wearable personal body associated device with various physical configurations |
EP3106092A3 (en) | 2011-04-29 | 2017-03-08 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
JP2014516644A (en) | 2011-04-29 | 2014-07-17 | セブンス センス バイオシステムズ,インコーポレーテッド | Devices and methods for collection and / or manipulation of blood spots or other body fluids |
US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
AU2012249692A1 (en) | 2011-04-29 | 2013-11-14 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving fluids |
US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
CN103827914A (en) | 2011-07-21 | 2014-05-28 | 普罗秋斯数字健康公司 | Mobile communication device, system, and method |
WO2013058879A2 (en) | 2011-09-02 | 2013-04-25 | The Regents Of The University Of California | Microneedle arrays for biosensing and drug delivery |
US9235683B2 (en) | 2011-11-09 | 2016-01-12 | Proteus Digital Health, Inc. | Apparatus, system, and method for managing adherence to a regimen |
MY182541A (en) | 2012-07-23 | 2021-01-25 | Proteus Digital Health Inc | Techniques for manufacturing ingestible event markers comprising an ingestible component |
UA116783C2 (en) | 2012-10-18 | 2018-05-10 | Протеус Діджитал Хелс, Інк. | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
WO2014120669A1 (en) | 2013-01-29 | 2014-08-07 | Proteus Digital Health, Inc. | Highly-swellable polymeric films and compositions comprising the same |
JP5941240B2 (en) | 2013-03-15 | 2016-06-29 | プロテウス デジタル ヘルス, インコーポレイテッド | Metal detector device, system and method |
JP6498177B2 (en) | 2013-03-15 | 2019-04-10 | プロテウス デジタル ヘルス, インコーポレイテッド | Identity authentication system and method |
EP3968263A1 (en) | 2013-06-04 | 2022-03-16 | Otsuka Pharmaceutical Co., Ltd. | System, apparatus and methods for data collection and assessing outcomes |
US20160147958A1 (en) * | 2013-07-26 | 2016-05-26 | Koninklijke Philips N.V. | Computerization and visualization of clinical rules and definitions for patient monitoring systems |
US9796576B2 (en) | 2013-08-30 | 2017-10-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
MX356850B (en) | 2013-09-20 | 2018-06-15 | Proteus Digital Health Inc | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping. |
JP2016537924A (en) | 2013-09-24 | 2016-12-01 | プロテウス デジタル ヘルス, インコーポレイテッド | Method and apparatus for use with electromagnetic signals received at frequencies that are not accurately known in advance |
US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
US11051543B2 (en) | 2015-07-21 | 2021-07-06 | Otsuka Pharmaceutical Co. Ltd. | Alginate on adhesive bilayer laminate film |
CN108699585A (en) * | 2016-02-23 | 2018-10-23 | 皇家飞利浦有限公司 | Method for progress original place detection of addling to breast milk |
WO2017213237A1 (en) | 2016-06-10 | 2017-12-14 | テルモ株式会社 | Oxygen measurement device |
EP3487393A4 (en) | 2016-07-22 | 2020-01-15 | Proteus Digital Health, Inc. | Electromagnetic sensing and detection of ingestible event markers |
US10820831B2 (en) | 2016-10-26 | 2020-11-03 | Proteus Digital Health, Inc. | Methods for manufacturing capsules with ingestible event markers |
US12109032B1 (en) | 2017-03-11 | 2024-10-08 | Biolinq Incorporated | Methods for achieving an isolated electrical interface between an anterior surface of a microneedle structure and a posterior surface of a support structure |
US11045142B1 (en) | 2017-04-29 | 2021-06-29 | Biolinq, Inc. | Heterogeneous integration of silicon-fabricated solid microneedle sensors and CMOS circuitry |
EP3506533B1 (en) | 2017-12-29 | 2022-03-30 | Nokia Technologies Oy | Sensing apparatus and system |
US11478194B2 (en) | 2020-07-29 | 2022-10-25 | Biolinq Incorporated | Continuous analyte monitoring system with microneedle array |
SE2330048A1 (en) | 2021-05-08 | 2023-01-25 | Biolinq Incorporated | Fault detection for microneedle array based continuous analyte monitoring device |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4615340A (en) * | 1985-02-27 | 1986-10-07 | Becton, Dickinson And Company | Sensor assembly suitable for blood gas analysis and the like and the method of use |
IL89159A0 (en) * | 1989-02-02 | 1989-09-10 | Optical Chemical Tech Oct | Medical probe |
ES2099182T3 (en) * | 1991-06-26 | 1997-05-16 | Ppg Industries Inc | ELECTROCHEMICAL SENSOR ASSEMBLY. |
AT397458B (en) * | 1992-09-25 | 1994-04-25 | Avl Verbrennungskraft Messtech | SENSOR ARRANGEMENT |
US5375604A (en) * | 1992-12-11 | 1994-12-27 | Siemens Medical Electronics, Inc. | Transportable modular patient monitor |
DE4329898A1 (en) * | 1993-09-04 | 1995-04-06 | Marcus Dr Besson | Wireless medical diagnostic and monitoring device |
US5474065A (en) * | 1994-04-04 | 1995-12-12 | Graphic Controls Corporation | Non-invasive fetal probe |
US6058321A (en) * | 1995-09-07 | 2000-05-02 | Swayze; Claude R. | Instrument for continuously monitoring fetal heart rate and intermittently monitoring fetal blood pH and method of use |
JPH10314149A (en) * | 1997-05-20 | 1998-12-02 | Casio Comput Co Ltd | Probe exchangeable electric measurement device, probe management method and pulse oximeter |
GB9815667D0 (en) * | 1998-07-17 | 1998-09-16 | Medinnova Sf | Device |
AU2032400A (en) * | 1998-11-25 | 2000-06-19 | Ball Semiconductor Inc. | Monitor for interventional procedures |
JP4189787B2 (en) * | 2001-03-06 | 2008-12-03 | 日本光電工業株式会社 | Biological information display monitor and system |
CA2446488A1 (en) * | 2001-05-07 | 2002-11-14 | Cardiosafe International Ag | Device for monitoring a patient |
DE10141732A1 (en) * | 2001-08-25 | 2003-03-06 | Horst Frankenberger | Method and device for long-term determination of the concentration of at least one substance in a body fluid |
US6616614B2 (en) * | 2001-09-18 | 2003-09-09 | Keimar Corporation | Apparatus and method for ascertaining cardiac output and other parameters |
US6879850B2 (en) * | 2002-08-16 | 2005-04-12 | Optical Sensors Incorporated | Pulse oximeter with motion detection |
US7539537B2 (en) * | 2002-10-03 | 2009-05-26 | Scott Laboratories, Inc. | Systems and methods for providing sensor fusion |
US20040138688A1 (en) * | 2002-10-09 | 2004-07-15 | Jean Pierre Giraud | Lancet system including test strips and cassettes for drawing and sampling bodily material |
-
2005
- 2005-09-08 BR BRPI0514953-3A patent/BRPI0514953A/en not_active IP Right Cessation
- 2005-09-08 EP EP05778573A patent/EP1788933A1/en not_active Withdrawn
- 2005-09-08 CN CNA2005800298151A patent/CN101026996A/en active Pending
- 2005-09-08 CA CA002578078A patent/CA2578078A1/en not_active Abandoned
- 2005-09-08 WO PCT/GB2005/003461 patent/WO2006027586A1/en active Application Filing
- 2005-09-08 JP JP2007530764A patent/JP2008512162A/en active Pending
- 2005-09-08 KR KR1020077005433A patent/KR20070052781A/en not_active Application Discontinuation
- 2005-09-08 AU AU2005281502A patent/AU2005281502A1/en not_active Abandoned
-
2007
- 2007-03-14 NO NO20071363A patent/NO20071363L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2008512162A (en) | 2008-04-24 |
AU2005281502A1 (en) | 2006-03-16 |
BRPI0514953A (en) | 2008-07-01 |
NO20071363L (en) | 2007-06-06 |
WO2006027586A1 (en) | 2006-03-16 |
EP1788933A1 (en) | 2007-05-30 |
KR20070052781A (en) | 2007-05-22 |
CN101026996A (en) | 2007-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2578078A1 (en) | Sensor | |
US20080319278A1 (en) | Sensor | |
US7826880B2 (en) | Electrochemical sensor for in-vivo or ex-vivio measurements of the carbon dioxide partial pressure of living tissue | |
US8003401B2 (en) | Carbon dioxide sensor and method of determining partial pressure of carbon dioxide | |
JPH08512213A (en) | Remotely sensed pressure measurement catheter apparatus and method | |
US20230093510A1 (en) | Membrane sealing for a physiological sensor | |
WO2004058057A1 (en) | Sensor device for monitoring perfusion of tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |